As we’ve noted in some recent blog posts (here and here, for instance), our team at Antibody Solutions is joining the global scientific community in the collective fight against SARS-CoV-2 and its mutations. That includes both research conducted on behalf of our clients and our own discoveries.
It’s that latter effort that led to the data we shared (virtually) at last week's Keystone eSymposia, "Antibodies and Vaccines as Drugs for COVID-19.”
Here’s a super-short summary: Using our antibody discovery platform and in-house modeling software, we sought to generate antibodies with fine specificity to each of the three sites on the spike protein that could be used to analyze virus infection and serve as potential therapeutic antibody leads. And here’s the five-minute video of our virtual presentation:
Keystone once again served up some fascinating science during the January 13-14 virtual symposia, and we were honored to present our initial findings there. (If you registered for the conference, you can view all the recorded research presentations at your convenience.)
We invite you also to download this poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.
We would welcome your feedback on our research and approach, so please let us know what you think by contacting us here. And get in touch if we can be of any help with your research into vaccines and therapeutics for SARS-CoV-2 or other targets.
Author of more than 40 publications, John’s current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.